| pubmed-article:18356603 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C0282440 | lld:lifeskim |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C1963724 | lld:lifeskim |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C1096777 | lld:lifeskim |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C1512900 | lld:lifeskim |
| pubmed-article:18356603 | lifeskim:mentions | umls-concept:C1711426 | lld:lifeskim |
| pubmed-article:18356603 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18356603 | pubmed:dateCreated | 2008-3-21 | lld:pubmed |
| pubmed-article:18356603 | pubmed:abstractText | We aimed to see if structured treatment interruption (STI) could be supported safely with the use of two cycles of IL-2 (4.5 MIU q12h subcutaneously 5 days) before STI to prolong the time before therapy restarted. | lld:pubmed |
| pubmed-article:18356603 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18356603 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18356603 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18356603 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18356603 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18356603 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18356603 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:18356603 | pubmed:issn | 1473-5571 | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:ClotetBonaven... | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:LampeFionaF | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:FisherMartinM | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:KatlamaChrist... | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:YouleMikeM | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:AngusBrianB | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:PhillipsAndre... | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:WilliamsIanI | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:DuvivierClaud... | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:PostFrank AFA | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:TambussiGuise... | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:BabikerAbdulA | lld:pubmed |
| pubmed-article:18356603 | pubmed:author | pubmed-author:TILT Trial... | lld:pubmed |
| pubmed-article:18356603 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18356603 | pubmed:day | 30 | lld:pubmed |
| pubmed-article:18356603 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:18356603 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18356603 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18356603 | pubmed:pagination | 737-40 | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:meshHeading | pubmed-meshheading:18356603... | lld:pubmed |
| pubmed-article:18356603 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18356603 | pubmed:articleTitle | TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. | lld:pubmed |
| pubmed-article:18356603 | pubmed:affiliation | Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK. brian.angus@ndm.ox.ac.uk | lld:pubmed |
| pubmed-article:18356603 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18356603 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
